Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 38, Issue 9

Issues

Gene Amplification as Means for Determining Therapeutic Strategies in Human Cancers

Gregory J. Tsongalis / Richard W. Cartun / Andrew Ricci Jr.
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2000.121

Abstract

Pharmacogenomic analysis aspires to identify individuals with specific genetic characteristics in order to predict a positive response or reduce a negative response to a therapeutic modality. While the search continues for the many single nucleotide polymorphisms which will be used in such genetic analyses, other genetic alterations in specific cell types have proven useful in determining the potential for response to therapy. One such genetic alteration is amplification of entire gene sequences which results in overexpression of a gene product or protein. Amplification of the HER2 (neu, erbB-2) oncogene is found in up to 35% of human breast cancers and is associated with a poor prognosis. In addition, this genetic alteration may predict response to various therapeutic modalities. Assays are available to detect the HER2 protein receptor or copies of the HER2 gene sequence to determine eligibility for Herceptin treatment or adriamycin treatment in node positive patients, respectively. This model represents a somatic event used in the functional determination of a therapeutic strategy.

About the article

Published Online: 2005-06-01

Published in Print: 2000-09-18


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 38, Issue 9, Pages 837–839, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2000.121.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Martha Weinar, Kathleen Calzone, and Bridget Le Grazie
Oncology Nursing Forum, 2003, Volume 30, Number 6, Page 921
[2]
Pothur R Srinivas, Barnett S Kramer, and Sudhir Srivastava
The Lancet Oncology, 2001, Volume 2, Number 11, Page 698
[3]
Gregory J Tsongalis and Andrew Ricci
Clinical Biochemistry, 2003, Volume 36, Number 2, Page 89
[4]
Patrick R Benusiglio
Pharmacogenomics, 2008, Volume 9, Number 7, Page 825
[5]
Satoshi Tanaka, Ikuo Kobayashi, Satoshi Utsuki, Hidehiro Oka, Kiyotaka Fujii, Takashi Watanabe, Tadashi Nagashima, and Tomokatsu Hori
International Journal of Cancer, 2003, Volume 103, Number 1, Page 67

Comments (0)

Please log in or register to comment.
Log in